Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial

Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial

<p><strong>Aims</strong></p> <p>To evaluate 1,5‐anhydroglucitol (1,5‐AG) according to clinical outcomes and assess the effects of glucose‐ and blood pressure‐lowering interventions on change in 1,5‐AG levels in people with type 2 diabetes.</p> <p><strong...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Selvin, E, Wang, D, McEvoy, JW, Juraschek, SP, Lazo, M, Hamet, P, Cooper, ME, Marre, M, Williams, B, Harrap, S, Chalmers, J, Woodward, M
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	Wiley 2019

Ижил төстэй зүйлс

Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial
-н: Rahman, F, зэрэг
Хэвлэсэн: (2019)

Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism
-н: Man Li, зэрэг
Хэвлэсэн: (2017-06-01)

Data for serum 1,5 anhydroglucitol concentration in different populations
-н: Marciane Welter, зэрэг
Хэвлэсэн: (2018-10-01)

The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus
-н: Haiying Xu, зэрэг
Хэвлэсэн: (2024-10-01)

The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients
-н: Eduardo Moraes Leao Peixoto, зэрэг
Хэвлэсэн: (2014-10-01)

The use of 1,5 anhydroglucitol level as a clinical test to differentiate subtypes of diabetes
-н: Owen, K, зэрэг
Хэвлэсэн: (2009)

Intensive glucose lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial
-н: Ohkuma, T, зэрэг
Хэвлэсэн: (2019)

Pemeriksaan 1,5-Anhydroglucitol, Suatu Hal Baru dalam Pemeriksaan Prediabetes
-н: Reza Febryan
Хэвлэсэн: (2024-03-01)

Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes
-н: Ha Yeong Yoo, зэрэг
Хэвлэсэн: (2015-12-01)

The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications
-н: Huijuan Xu, зэрэг
Хэвлэсэн: (2024-05-01)

Side-effects and tolerability of combination blood pressure lowering according to blood pressure levels – an analysis of the PROGRESS and ADVANCE trials
-н: Atkins, A, зэрэг
Хэвлэсэн: (2017)

Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
-н: Pal, A, зэрэг
Хэвлэсэн: (2010)

History of lower-limb complications and risk of cancer death in people with type 2 diabetes
-н: Kamel Mohammedi, зэрэг
Хэвлэсэн: (2021-01-01)

Prognostic Value of Serum 1,5-anhydroglucitol Levels in Patients with Acute Myocardial Infarction
-н: Yijia Wang, зэрэг
Хэвлэсэн: (2022-12-01)

Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance
-н: Thyparambil Aravindakshan Pramodkumar, зэрэг
Хэвлэсэн: (2016-01-01)

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
-н: Zoungas, S, зэрэг
Хэвлэсэн: (2009)

1,5-anhydroglucitol in diabetes: its role in diagnostics, screening, glycemic status assessment, and the prediction of complications
-н: V. V. Klimontov, зэрэг
Хэвлэсэн: (2020-08-01)

Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol
-н: Ji-Eun Lee
Хэвлэсэн: (2015-06-01)

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
-н: Patel, A, зэрэг
Хэвлэсэн: (2008)

Lowering blood pressure reduces renal events in type 2 diabetes.
-н: de Galan, B, зэрэг
Хэвлэсэн: (2009)

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
-н: Perkovic, V, зэрэг
Хэвлэсэн: (2013)

1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus
-н: Masahiro Usui, зэрэг
Хэвлэсэн: (2020-09-01)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
-н: Rådholm, K, зэрэг
Хэвлэсэн: (2018)

Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome
-н: Gong Su, зэрэг
Хэвлэсэн: (2020-05-01)

Estimating individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes
-н: Woodward, M, зэрэг
Хэвлэсэн: (2016)

Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis
-н: Kenji Tanaka, зэрэг
Хэвлэсэн: (2021-08-01)

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study
-н: Mohammedi, K, зэрэг
Хэвлэсэн: (2016)

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
-н: Mohammedi, K, зэрэг
Хэвлэсэн: (2017)

Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes
-н: Jian Zhou, зэрэг
Хэвлэсэн: (2021-03-01)

1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
-н: Hannah Seok, зэрэг
Хэвлэсэн: (2015-04-01)

Evaluation of 1,5-Anhydroglucitol as a Biomarker for Type 2 Diabetes Mellitus in Patients without Overt Nephropathy
-н: Luiza Cristina Gobor, зэрэг
Хэвлэсэн: (2021-10-01)

Detection of 1,5-anhydroglucitol as a Biomarker for Diabetes Using an Organic Field-Effect Transistor-Based Biosensor
-н: Hiroyuki Furusawa, зэрэг
Хэвлэсэн: (2018-08-01)

Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker
-н: Ben A. Kappel, зэрэг
Хэвлэсэн: (2021-06-01)

Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes
-н: Yun Shen, зэрэг
Хэвлэсэн: (2020-01-01)

Nonlinear association of 1,5-anhydroglucitol with the prevalence and severity of coronary artery disease in chinese patients undergoing coronary angiography
-н: Ruiyue Yang, зэрэг
Хэвлэсэн: (2022-09-01)

Evaluation of serum 1,5-anhydroglucitol levels as hyperglycemic indicator in patients with newly diagnosed type 2 diabetes mellitus
-н: Ashok Vanagamudi, зэрэг
Хэвлэсэн: (2022-01-01)

Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes
-н: Mohammedi, K, зэрэг
Хэвлэсэн: (2016)

The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients
-н: Yijia Wang, зэрэг
Хэвлэсэн: (2024-07-01)

1,5-Anhydroglucitol promotes pre-B acute lymphocytic leukemia progression by driving glycolysis and reactive oxygen species formation
-н: Huasu Zhu, зэрэг
Хэвлэсэн: (2023-02-01)

The impact of level of education on vascular events and mortality in patients with type 2 Diabetes mellitus: results from the ADVANCE study
-н: Blomster, J, зэрэг
Хэвлэсэн: (2017)